They have been big winners for Myriad, including Colaris for colorectal cancer and Prolaris, which assesses the form of prostate cancer to determine its nature and avoid unnecessary surgeries.

FORBES: Myriad Genetics: This Leading Developer of Diagnostic Products Is Catching The Eye Of Potential Big Pharma Partners